CircuLex Mouse/Rat PCSK9 ELISA Kit

CircuLex Mouse/Rat PCSK9 ELISA Kit.



The CycLex Research Product CircuLex Mouse/Rat PCSK9 ELISA Kit is used for the quantitative measurement of Mouse and Rat PCSK9 in serum, plasma, cell culture medium and other biological media. It can be used for 96 Assays.

Target: PCSK9
Product Type: ELISA Kit
Size: 96 Assays
Application: ELISA
Research Area / Disease: Metabolism


  • Microplate
  • 10X Wash Buffer
  • Dilution Buffer
  • Mouse PSCK9 Standard
  • HRP conjugated Detection Antibody
  • Substrate Reagent
  • Stop Solution


  1. Tang, Vi T., et al. “Hepatic inactivation of murine Surf4 results in marked reduction in plasma cholesterol.” bioRxiv (2022).
  2. Levine, Joshua A., et al. “Role of PAI-1 in hepatic steatosis and dyslipidemia.” Scientific reports 11.1 (2021): 1-13.
  3. Momtazi-Borojeni, Amir Abbas, et al. “Impact of PCSK9 Immunization on Glycemic Indices in Diabetic Rats.” Journal of Diabetes Research 2021 (2021).
  4. Momtazi-Borojeni, Amir Abbas, et al. “Effects of immunisation against PCSK9 in mice bearing melanoma.” Archives of Medical Science 16.1 (2020): 189-199.
  5. Momtazi-Borojeni, Amir Abbas, et al. “Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis.” BMC medicine 17.1 (2019): 1-15.
  6. Momtazi-Borojeni, Amir Abbas, et al. “Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer.” Archives of Medical Science 15.3 (2019): 559-569.
  7. Momtazi-Borojeni, Amir Abbas, et al. “Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system.” Atherosclerosis 283 (2019): 69-78.
  8. Mikaeeli, Sepideh. PCSK9 Mutants and PACE4 as a Novel PCSK9 Regulator. McGill University (Canada), 2019.
  9. Ding Z et al. PCSK9 expression in the ischemic heart and its relationship to infarct size, cardiac function and development of autophagy. Cardiovasc Res. (2018) In press.
  10. Xu YX et al. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol. Atherosclerosis (2017) In press.
  11. Lintner NG et al. Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain. PLoS Biol. 15, e2001882 (2017)
  12. Haas ME et al. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia. Circulation 134, 61-72 (2016)
  13. Sock ET et al. Combined Effects of Rosuvastatin and Exercise on Gene Expression of Key Molecules Involved in Cholesterol Metabolism in Ovariectomized Rats. PLoS One. 11, e0159550 (2016)
  14. An D et al. Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics. Sci Rep. 5, 17559 (2015)
    Berger JM et al. PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension. Atherosclerosis 239, 252-9 (2015)
  15. Butkinaree C et al. Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other. J Biol Chem. 290, 18609-20 (2015)
  16. Carrier B et al. Alpha-lipoic acid reduces LDL-particle number and PCSK9 concentrations in high-fat fed obese Zucker rats. PLoS One. 9, e90863 (2014),
  17. Galabova G et al. Peptide-based anti-PCSK9 vaccines – an approach for long-term LDLc management. PLoS One. 9, e114469 (2014),
  18. Sasaki M et al. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways. Arterioscler Thromb Vasc Biol. 34, 1171-8 (2014)
  19. Chen XW et al. SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion. Elife. 2, e00444 (2013)


  1. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M (2003) Proc Natl Acad Sci USA 100:928–933.
  2. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, et al. (2003) Nat Genet 34:154–156.
  3. Leren TP (2004) Clin Genet 65:419–422.
  4. Allard D, Amsellem S, Abifadel M, Trillard M, Devillers M, Luc G, Krempf M, Reznik Y, Girardet JP, Fredenrich A, et al. (2005) Hum Mutat 26:497.
  5. Cohen JC, Boerwinkle E, Mosley TH, Jr, Hobbs HH (2006) N Engl J Med 354, 1264–1272.
  6. Berge KE, Ose L, Leren TP (2006) Arterioscler Thromb Vasc Biol 26:1094–1100.
  7. Maxwell KN, Breslow JL (2004) Proc Natl Acad Sci USA 101:7100–7105.
  8. Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, Hammer RE, Moon YA, Horton JD (2005) Proc Natl Acad Sci USA 102:5374–5379.
  9. Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., and Horton, J. D. (2006) J. Clin. Investig. 116, 2995–3005
  10. Cameron, J., Holla, O. L., Ranheim, T., Kulseth, M. A., Berge, K. E., and Leren, T. P. (2006) Hum. Mol. Genet. 15, 1551–1558
  11. Zhang, D. W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., Cohen, J. C., and Hobbs, H. H. (2007) J. Biol. Chem. 282, 18602–18612
Code CY-8078
Product Type ELISA Kit
Size 96 Assays
Application ELISA